Business
Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF
NAPLES, Fla., Nov. 8, 2021 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"NAPLES, Fla., Nov. 8, 2021 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) (\"Enveric\" or the \"Company\"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced it has been included in the new AdvisorShares Psychedelics ETF, trading under the ticker symbol \"PSIL\" on the NYSE Arca exchange. \n\n \n \n \n \n \n \n\n \nPSIL is an ETF that focuses on investments in biotechnology, pharmaceutical and life sciences companies that are leading the nascent but advancing psychedelic industry. Medical research has indicated various psychedelic assets offer enormous medical and therapeutic potential to treat the prevalent mental health crisis and neurological disorder. The ETF is actively managed by Dan Ahrens, Chief Operating Officer of AdvisorShares, and concentrates its investments in companies receiving the majority of their net revenue or allocating the majority of their assets from psychedelic drugs.\n\"The inclusion of Enveric Biosciences in AdvisorShares Psychedelics ETF is an important milestone for us as it validates Enveric's platform of next-generation psychedelic and cannabinoid medicines. The addition of Enveric will also help bolster our visibility and exposure across the global investment community,\" said Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences. \"We are proud to be acknowledged by PSIL as an emerging leader in the fast-growing psychedelic industry.\" \nYou can find additional information on the AdvisorShares Psychedelics ETF here.\nAbout Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com. \nAbout AdvisorShares AdvisorShares is a leading provider of actively managed ETFs. For financial professionals and investors requesting more informatio...